Short answer
Quest Diagnostics (DGX) filed an 8-K current report with the SEC on March 12, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers), Item 7.01 (Regulation FD Disclosure). Timothy Wentworth, ex-CEO of Walgreens Boots Alliance, elected to DGX Board on March 9, 2026.
Quest Diagnostics 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Timothy Wentworth, ex-CEO of Walgreens Boots Alliance, elected to DGX Board on March 9, 2026
- Appointed to Compensation & Leadership Development and Quality & Compliance Committees
- Prorated RSU grant of ~$43,000 awarded upon joining; standard non-employee director compensation applies
- Healthcare industry veteran adds operational depth; Walgreens background relevant to DGX's lab/pharmacy channel strategy
Item 7.01 · Regulation FD Disclosure
- Quest Diagnostics elected Mr. Wentworth to its Board of Directors
- Board composition change: new director additions can signal strategic shifts in oversight or targeted expertise
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Quest Diagnostics 8-K filings
Get the next DGX 8-K as it lands
Follow DGX for push alerts, or ask the research agent what this filing means.